Overall, HDACi monotherapy is effective in MPN however not well tolerated in ET and PV patients, where published studies show significant drop out due to toxicity, even if HDACi monotherapy clearly is active and also decreases JAK2 mutation burden in PV and ET [78,79,80]. This evidence concerns the gene JAK2 and myeloproliferative disorder.